Panacea Biotec Limited has informed the Exchange regarding Change in Director(s) of the company.
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Panacea Biotec reported standalone revenue of Rs 43,149 lakh for FY 2025-26, up 32% from Rs 32,647 lakh in the previous year. However, the company recorded a standalone net loss of Rs 2,988 lakh, worse than the Rs 1,523 lakh loss in FY 2024-25. Consolidated revenue grew to Rs 65,667 lakh from Rs 57,975 lakh. The board decided to skip dividend payment due to losses during the year. Mr. Rajinder Singh Manku was appointed as a non-executive independent director for a 5-year term effective July 1, 2026. Note 4 of the financial statements explicitly mentions that the company's retained earnings are negative at Rs 21,782 lakh, indicating uncertainty about the company's ability to continue as a going concern.
The company continues to burn cash with mounting losses despite strong revenue growth, raising serious going concern doubts. Shareholders should be cautious as the auditors have flagged material uncertainty about the company's viability, though the audit opinion remains unmodified.